Mometasonfuroat Puren (Mometasone Furoate)

Mometasone furoate is a synthetic glucocorticoid that binds to glucocorticoid receptors in the cells lining the nasal mucosa. This binding alters gene expression, leading to reduced production of inflammatory mediators such as cytokines and prostaglandins, which in turn diminishes swelling, mucus production, and allergic symptoms.

The specific dose and frequency of Mometasonfuroat Puren are determined by the prescribing healthcare professional based on the patient’s age, severity of symptoms, and clinical response. Patients should follow the prescriber’s instructions and the product labeling for proper administration.

Safety data for mometasone furoate nasal spray in pregnancy and lactation are limited. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss potential risks and benefits with their healthcare provider before using the product.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, and will request verification of trade or institutional credentials. After confirmation, the team provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Mometasonfuroat Puren contains mometasone furoate, which is a high‑potency, once‑daily nasal corticosteroid. Compared with older agents such as fluticasone or budesonide, mometasone often provides comparable or superior symptom control with a low systemic absorption profile, making it a preferred option for many clinicians managing allergic rhinitis and nasal polyps.

Store the nasal spray at room temperature, below 25 °C (77 °F). Keep the product in its original packaging, protect it from moisture, direct sunlight, and extreme heat. Do not freeze the spray, and ensure the cap is tightly closed when not in use.

Mometasonfuroat Puren is administered as a nasal spray. The patient should gently blow the nose, tilt the head slightly forward, insert the nozzle into one nostril, and spray the prescribed number of sprays while breathing in gently through the nose. The same procedure is repeated in the other nostril if directed by the prescriber.

Serious risks, though rare, include nasal septal perforation, adrenal suppression leading to systemic glucocorticoid effects, cataracts or glaucoma, and severe allergic reactions such as anaphylaxis. Patients should seek immediate medical attention if they experience unusual nosebleeds, vision changes, severe headache, or signs of systemic steroid exposure.

Individuals with known hypersensitivity to mometasone furoate or any component of the formulation should avoid using the spray. It is also contraindicated in patients who have active, untreated infections of the nasal mucosa or those who have recently undergone nasal surgery without physician approval.